Gapping up
In reaction to strong earnings/guidance:
- ASNA +18.5%, JBL +4.1%
Other news:
- TLRY +18.7% (announces successful export of medical cannabis from Canada to Australia for distribution to critically ill pediatric patients)
- ARNA +6.3% (Arena Pharma reports positive phase 2a Results for olorinab in patients with abdominal pain associated with Crohn's Disease; intends to progress the olorinab clinical program targeting gastrointestinal pain)
- BAS +4.8% (Key Energy Services proposed to combine with Basic Energy Services in an all-stock merger; to be accretive to both sets of shareholders after consideration of cost synergies)
- PSTI +4.6% (Pluristem Therapeutics granted Orphan Drug Designation by the FDA for the Company's PLX cell therapy for the treatment of graft failure and incomplete hematopoietic recovery following hematopoietic cell transplantation)
- VSTM +3% (announces FDA approval for COPIKTRA)
- SNAP +2.2% (Snap +3% amid turmoil at Facebook's (FB) Instagram, with co-founders Kevin Systrom and Mike Krieger having resigned)
- SBGL +2% (announces milestones reached in terms of the Altar transaction)
- RETA +2% (announces positive, final results from the IgA nephropathy and type 1 diabetic chronic kidney disease (T1D CKD) cohorts of PHOENIX)
- TNC +1.3% (to acquire Gaomei Cleaning Equipment Company)
- KIRK +1.1% (appoints Steve Woodward as CEO, effective October 22; authorizes new $10 mln stock repurchase program)
Analyst comments:
- WK +4.2% (upgraded to Outperform from Neutral at Robert W. Baird)
- CGC +3.4% (initiated with a Buy at The Benchmark Company)
- SQ +2.7% (target raised to new Street-high $125 from $86 at Nomura-Instinet)
- SAIC +1.5% (upgraded to Buy from Hold at Jefferies)
- CLX +1.5% (upgraded to Buy from Hold at Argus)
- HP +1.1% (upgraded to Buy from Neutral at B. Riley FBR)
- DG +1.1% (resumed with a Buy from Neutral at Buckingham Research)
- BCPC +0.9% (initiated with a Buy at H.C. Wainwright)
- WELL +0.8% (initiated with a Overweight at Barclays)
![]()